This inventor holds 2 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Santen Pharmaceutical Co., Ltd.. Active years: 2013-2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2013-2014
Title: Yumi Hagiwara: Innovator in Glucocorticoid Receptor Agonists
Introduction
Yumi Hagiwara is a notable inventor based in Japan, recognized for his contributions to the field of pharmacology. His work primarily focuses on glucocorticoid receptor agonists, which have significant implications for medical treatments.
Latest Patents
Hagiwara's most recent patent is titled "Glucocorticoid Receptor Agonist Comprising 2,2,4-Trimethyl-6-Phenyl-1,2-Dihydroquinoline Derivatives Having Substituted Oxy Group." This invention relates to glucocorticoid receptor agonists comprised of a compound represented by a specific formula. The compound is a 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivative or a salt thereof, showcasing novel pharmacological effects.
Career Highlights
Yumi Hagiwara is currently employed at Ayumi Pharmaceutical Corporation, where he continues to innovate in the field of pharmacology. His research has led to advancements in understanding the effects of glucocorticoid receptor agonists.
Collaborations
Hagiwara collaborates with several esteemed colleagues, including Masatomo Kato and Miwa Takai, who contribute to his research endeavors.
Conclusion
Yumi Hagiwara's work in glucocorticoid receptor agonists represents a significant advancement in pharmacological research. His contributions continue to influence the field and pave the way for future innovations.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile